The bacterial and viral antigen experts

The Native Antigen Company (NAC) specialises in the R&D and scale up manufacturing of highly pure viral and bacterial native antigens. NAC's antigens are used primarily by pharmaceutical and IVD manufacturers in vaccine research and serology where high specificity and sensitivity are vital. As well as offering antigens from a rapidly expanding portfolio, NAC undertakes bespoke product development and partnering.

Latest Product News

Japanese Encephalitis Virus NS1 protein

The Native Antigen Company Limited (‘NAC’: Oxford, UK) announces the launch of a new antigen product; Japanese Encephalitis Virus (JEV) NS1. The protein is derived from a human cell line using a proprietary human c...

CMV gH Pentamer Complex

The Native Antigen Company (NAC) announces the release of a commercially available human cytomegalovirus (hCMV) glycoprotein H (gH) complex comprising five viral proteins (gH, gL, UL128, UL130, and UL131a). hCMV...

World First: All 4 Dengue Virus NS1 Serotypes from human cell lines

The Native Antigen Company (NAC) announces a world first: the release of all 4 Dengue Virus NS1 serotypes from human cell lines. All four DENV NS1 serotypes have been manufactured in response to the unmet need for ...

More Antigen Product News

"For several of our dengue research projects at the University of California, Berkeley, we had been searching for purified DENV NS1 protein from all four serotypes which could offer the advantage of being derived from a mammalian expression system. In our hands, NAC's DENV NS1 proteins have performed extremely well in a range of applications and have helped advance our research program".

Professor Eva Harris, Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley.